Virios Therapeutics, Inc. (Nasdaq: VIRI) is a biotechnology company focused on advancing novel antiviral therapies to treat diseases associated with a viral triggered abnormal immune response, such as fibromyalgia. Overactive immune response related to activation of tissue resident Herpes Simplex Virus-1 has been postulated to be a potential root cause of chronic illnesses such as FM, irritable bowel disease, chronic fatigue syndrome and functional somatic syndrome, all of which are characterized by a waxing and waning manifestation of disease. Our lead development candidate, IMC-1, is a novel, proprietary, fixed dose combination of famciclovir and celecoxib. IMC-1 represents a novel combination antiviral therapy designed to synergistically suppress HSV-1 activation and replication, with the end goal of reducing viral mediated disease burden.
Company HQ State:
Company HQ Country:
Main Therapeutic Focus:
Lead Product in Development:
IMC-1, novel, proprietary, fixed dose combination of famciclovir & celecoxib, to treat fibromyalgia
Development Phase of Primary Product:
Number Of Unlicensed Products (For Which You Are Seeking Partners):